問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiology

Division of Hematology & Oncology

Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung (在職)

Division of Radiology

更新時間：2023-09-19

吳樹鏗Ag, Shu-Hang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

  • shng@cgmh.org.tw

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳樹鏗

List

26Cases

2021-09-01 - 2025-03-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-12-14 - 2024-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-05-12 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting4Sites

Terminated5Sites

2011-02-01 - 2014-01-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-10-01 - 2021-01-17

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-01-20 - 2025-08-15

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華
Taipei Veterans General Hospital

Division of Radiation Therapy

2020-06-01 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-10-01 - 2025-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2008-08-01 - 2011-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB